Obesity and Metabolic Syndrome: Causes, Health Risks and Treatment

Obesity is one of the defining health challenges of the 21st century. Over 1 billion adults worldwide are obese (BMI ≥30 kg/m²), with an additional 1.5 billion overweight (BMI 25–29.9 kg/m²). In China, overweight and obesity now affect approximately 50% of adults — a dramatic shift from the low prevalence of just two decades ago.

Obesity is not a lifestyle choice or a failure of willpower — it is a chronic, relapsing medical condition driven by complex interactions between genetics, environment, hormonal signalling, gut microbiome, sleep, and socioeconomic factors. It is the leading preventable risk factor for type 2 diabetes, cardiovascular disease, several cancers, non-alcoholic fatty liver disease (NAFLD), obstructive sleep apnoea, and osteoarthritis.

Effective treatment is available — and has been dramatically expanded by a new generation of GLP-1 receptor agonists and dual agonists that produce 15–25% body weight loss.

Defining Obesity

Body Mass Index (BMI)

BMI = weight (kg) ÷ height² (m²)

BMI (kg/m²)	Category
<18.5	Underweight
18.5–24.9	Healthy weight
25.0–29.9	Overweight
30.0–34.9	Obesity class I
35.0–39.9	Obesity class II
≥40.0	Obesity class III (severe)

Asian-specific thresholds: In East Asian (including Chinese) and South Asian populations, metabolic complications arise at lower BMI. Revised WHO thresholds for Asians:

• Overweight: BMI ≥23 kg/m²
• Obese: BMI ≥27.5 kg/m²

Central (Abdominal) Obesity

BMI does not distinguish fat distribution. Visceral adiposity — fat deposited within and around abdominal organs — is metabolically active and more harmful than subcutaneous fat. Measured by waist circumference:

• Men: waist ≥94 cm (Europe) / ≥90 cm (Asia): increased risk; ≥102 cm: high risk
• Women: waist ≥80 cm (Europe) / ≥80 cm (Asia): increased risk; ≥88 cm: high risk

Visceral fat produces pro-inflammatory adipokines, fatty acids, and cytokines that drive insulin resistance, dyslipidaemia, hypertension, and endothelial dysfunction — the foundations of cardiovascular risk.

The Metabolic Syndrome

Metabolic syndrome is a cluster of cardiometabolic risk factors that commonly occur together, driven by central obesity and insulin resistance. Diagnosis requires ≥3 of the following (IDF/AHA criteria):

Component	Threshold
Waist circumference	≥90 cm (men) / ≥80 cm (women) in Asians
Fasting glucose	≥5.6 mmol/L (or on diabetes medication)
Triglycerides	≥1.7 mmol/L (or on medication)
HDL cholesterol	<1.0 mmol/L men / <1.3 mmol/L women (or on medication)
Blood pressure	≥130/85 mmHg (or on antihypertensive medication)

Metabolic syndrome affects approximately 25–30% of adults globally and confers a 2× increased risk of cardiovascular events and a 5× increased risk of type 2 diabetes.

Health Consequences of Obesity

Metabolic

• Type 2 diabetes — 80% of T2DM patients are overweight or obese; adipose tissue-derived free fatty acids and inflammatory adipokines impair insulin signalling in liver, muscle, and fat
• Non-alcoholic fatty liver disease (NAFLD/MASLD) — excess fat accumulation in the liver; present in approximately 25% of the general population and 75–90% of obese individuals; can progress to non-alcoholic steatohepatitis (NASH/MASH) → cirrhosis → hepatocellular carcinoma
• Polycystic ovary syndrome (PCOS) — obesity worsens insulin resistance and androgen excess; weight loss alone can restore ovulation in many women with PCOS

Cardiovascular

• Hypertension — each 5 kg weight gain raises systolic BP by approximately 2–3 mmHg
• Dyslipidaemia — elevated triglycerides and LDL, reduced HDL
• Coronary artery disease — 2–3× increased risk
• Atrial fibrillation — obesity is the largest modifiable risk factor for AF
• Heart failure — obesity cardiomyopathy; increased cardiac workload

Cancer

Obesity is a recognised cause of at least 13 cancers: endometrial, breast (post-menopausal), colorectal, oesophageal, gastric, liver, pancreatic, kidney, ovarian, thyroid, multiple myeloma, meningioma, and gallbladder cancer. Proposed mechanisms include chronic inflammation, hyperinsulinaemia, sex hormone excess, and adipokine signalling.

Respiratory

• Obstructive sleep apnoea (OSA) — present in 40–70% of obese individuals; intermittent nocturnal hypoxia raises cardiovascular risk
• Obesity hypoventilation syndrome — inability to breathe deeply enough during sleep; leads to chronic respiratory failure
• Asthma — obesity worsens airway inflammation and mechanical loading

Musculoskeletal

• Osteoarthritis of weight-bearing joints (knees, hips) — each 1 kg weight gain increases knee load by approximately 4 kg per step
• Gout — hyperuricaemia from increased purine turnover

Psychosocial

• Depression and anxiety (bidirectional relationship with obesity)
• Stigmatisation and discrimination
• Reduced quality of life across all domains

Treatment

Effective obesity management requires a multimodal approach combining lifestyle, behavioural support, pharmacotherapy, and surgery where indicated.

Lifestyle Intervention

Dietary modification:

• A calorie deficit of 500–750 kcal/day produces approximately 0.5–1 kg/week weight loss
• No single optimal diet — low-carbohydrate, Mediterranean, very-low-calorie (800 kcal/day using meal replacements), and intermittent fasting all achieve similar outcomes at 12 months; adherence is the key determinant
• Very-low-calorie diets (800 kcal/day) using total diet replacement can produce 10–15 kg weight loss in 12 weeks and T2DM remission (DiRECT trial)

Physical activity:

• 150–300 minutes/week moderate aerobic exercise (walking, cycling, swimming)
• Resistance training preserves lean mass during weight loss
• Exercise alone produces modest weight loss (3–5 kg) but substantially improves cardiovascular fitness, metabolic risk factors, and mental health independent of weight

Behavioural therapy:

• Cognitive behavioural therapy (CBT) addressing eating patterns, emotional eating, and self-regulatory skills
• Commercial and NHS behavioural programmes: sustained behaviour change requires structured support, not information alone

Pharmacotherapy

Until recently, approved weight-loss medications had modest efficacy (5–7% body weight loss). The GLP-1 receptor agonist class has transformed this landscape.

GLP-1 receptor agonists:

Semaglutide (Wegovy) — 2.4 mg weekly subcutaneous injection:

• The STEP trials: average 14.9% body weight loss at 68 weeks vs 2.4% with placebo (STEP 1)
• Reduces cardiovascular events in obese adults with established CVD (SELECT trial: 20% reduction in MACE)
• Now approved for chronic weight management (Wegovy) separately from diabetes (Ozempic)

Liraglutide (Saxenda) — 3 mg daily injection: ~8% body weight loss; approved for weight management.

Dual GIP/GLP-1 agonists:

Tirzepatide (Mounjaro/Zepbound):

• Activates both GIP and GLP-1 receptors — superior to semaglutide in head-to-head trials (SURMOUNT-5: 20.2% vs 13.7% weight loss)
• SURMOUNT-1: up to 22.5% body weight loss at 72 weeks
• FDA approved for chronic weight management (Zepbound) and T2DM (Mounjaro)

These medications require ongoing use — weight is regained after discontinuation.

Orlistat — lipase inhibitor reducing fat absorption by 30%; modest weight loss (3 kg above placebo); GI side effects limit use.

Bariatric and Metabolic Surgery

For patients with BMI ≥40 (or ≥35 with obesity-related comorbidities, or ≥32.5 in Asian patients with T2DM), bariatric surgery achieves the most durable and substantial weight loss of any intervention:

Sleeve gastrectomy — most common procedure globally; approximately 75% of excess weight lost at 2 years; reduces gastric volume by ~80%, reduces ghrelin (hunger hormone); technically simpler; lower complication rate; not reversible.

Roux-en-Y gastric bypass (RYGB) — gold standard metabolic surgery; bypasses stomach and proximal small bowel; 75–80% excess weight lost; most effective for T2DM remission (metabolic effects independent of weight loss); more complex; dumping syndrome risk; nutritional monitoring required lifelong.

One anastomosis gastric bypass (OAGB / mini-bypass) — gaining popularity; good efficacy; technically simpler than RYGB.

Adjustable gastric band — largely abandoned due to inferior efficacy and high reoperation rate.

Outcomes of bariatric surgery:

• T2DM remission: 60–80% (gastric bypass); 50–60% (sleeve gastrectomy)
• Hypertension remission: 60–75%
• OSA resolution: 80–85%
• Significant reduction in cardiovascular events and all-cause mortality in long-term studies
• Lifelong nutritional supplementation required (vitamin B12, iron, calcium, vitamin D)

Obesity and Metabolic Disease Care in China

China's metabolic disease and bariatric surgery centres offer:

• Comprehensive obesity assessment: BMI, body composition (DEXA or bioimpedance), metabolic panel (glucose, insulin, HbA1c, lipids, liver enzymes, uric acid), sleep study for OSA, and cardiac risk assessment
• GLP-1 medication access: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro), and liraglutide available through specialist clinics; structured titration and monitoring
• High-volume bariatric surgery: sleeve gastrectomy, Roux-en-Y gastric bypass, and OAGB performed by experienced bariatric surgeons; laparoscopic approach standard; comprehensive pre-operative assessment and post-operative support
• Multidisciplinary metabolic team: bariatric surgeon, endocrinologist, dietitian, psychologist, and anaesthetist in a structured pre-operative programme
• Cost: care in China is generally less expensive than UK private treatment, but the hospital prices each case individually — ask us for the written quote before you commit.
• Full English care navigation from initial assessment through surgery and long-term follow-up

Contact a ChinaMedicalTour care navigator to arrange an obesity medicine consultation, bariatric surgery assessment, or GLP-1 medication review.

---

Medical content based on MSD Manuals and international obesity management guidelines. Evidence reviewed 2025.

Frequently Asked Questions

What comprehensive diagnostic evaluations are available for endocrine and metabolic disorders in China?

Tertiary endocrinology departments provide continuous glucose monitoring, comprehensive metabolic panels, hormone assays, thyroid fine-needle aspiration biopsy, and DEXA bone densitometry.

How do Chinese medical teams approach metabolic and chronic endocrine management?

Care combines clinical endocrinologist consultations, individualized pharmacological regimens, nutritional guidance, and multidisciplinary screening for cardiovascular and microvascular complications.

Can international visitors combine endocrine consultations with a general medical checkup?

Yes. Specialized endocrine evaluations can be coordinated alongside comprehensive executive checkups or specialist referrals to optimize traveling schedules.